VERAMYST
Total Payments
$5.9M
Transactions
608
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $34,560 | 1 | 0 |
| 2021 | $480,508 | 39 | 0 |
| 2020 | $1.2M | 66 | 0 |
| 2019 | $1.3M | 93 | 0 |
| 2018 | $1.0M | 115 | 0 |
| 2017 | $1.9M | 294 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.9M | 608 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY HZA114971, A MULTICENTRE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTR | GlaxoSmithKline, LLC. | $2.8M | 0 |
| A Phase IIb, 24 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once daily via a dry powder inhaler, versus placebo, in participants with asthma | GlaxoSmithKline, LLC. | $872,540 | 7 |
| VOICE ANALYSIS OF COPD PATIENTS WITH EXACERBATIONS (VOICE) | GlaxoSmithKline, LLC. | $752,145 | 0 |
| Study HZA114971, A Multicentre Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effects of a One Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg once daily on Growth Velocity in Prepubertal, Paediatric Subjects | GlaxoSmithKline, LLC. | $623,537 | 1 |
| A PHASE IIB, 24 WEEK, RANDOMIZED, DOUBLE-BLIND, 3 ARM PARALLEL GROUP S | GlaxoSmithKline, LLC. | $385,736 | 0 |
| Multi centre, Randomized, Double Blind, Parallel Group Study Evaluating the Effect of Fluticasone Furoate Vilanterol FF VI Inhalation Powder Once Daily Compared with Vilanterol VI Inhalation Powder Once Daily on Bone Mineral Density in Subjects with | GlaxoSmithKline, LLC. | $186,897 | 0 |
| PEAK INSPIRATORY FLOW (PIF) IN COPD | GlaxoSmithKline, LLC. | $172,800 | 0 |
| A randomized, double blind, placebo controlled, parallel group study of once daily inhaled Fluticasone Furoate Inhalation Powder for six weeks on the hypothalamic pituitaryadrenocortical axis of children aged 5 11 years with asthma | GlaxoSmithKline, LLC. | $68,914 | 0 |
| Assessment of FF VI and other ICS LABA s on overall healthcare costs and outcomes in patients with COPD in the US | GlaxoSmithKline, LLC. | $30,505 | 0 |
Top Doctors Receiving Payments for VERAMYST
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $5.9M | 547 |
| , M.D | Critical Care Medicine | Bloomington, IN | $7,715 | 10 |
| , M.D | Critical Care Medicine | Natchitoches, LA | $1,762 | 9 |
| , MD | Family Medicine | Goodyear, AZ | $1,461 | 7 |
| , M.D | Allergy | Grants Pass, OR | $1,293 | 7 |
| , MD | Family Medicine | Shelby, NC | $1,260 | 9 |
| , MD | Internal Medicine | Monroe, NC | $1,161 | 8 |
| , MD | Pulmonary Disease | Spartanburg, SC | $970.79 | 5 |
| , MD | Otolaryngology | Orangeburg, SC | $959.97 | 6 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $5.9M
Product Information
- Type Drug
- Total Payments $5.9M
- Total Doctors 8
- Transactions 608
About VERAMYST
VERAMYST is a drug associated with $5.9M in payments to 8 healthcare providers, recorded across 608 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2023. In 2023, $34,560 was paid across 1 transactions to 0 doctors.
The most common payment nature for VERAMYST is "Unspecified" ($5.9M, 100.0% of total).
VERAMYST is associated with 9 research studies, including "STUDY HZA114971, A MULTICENTRE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTR" ($2.8M).